Vanguard Capital Wealth Advisors Biogen Inc. Transaction History

Vanguard Capital Wealth Advisors

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 17, 2023	SELL	$252.44 - $306.72 $12,622 - $15,336	-50 Reduced 2.13%	2,300 $0
Q1 2022 Apr 29, 2022	SELL	$193.77 - $244.14 $19,377 - $24,414	-100 Reduced 4.08%	2,350 $494,000
Q4 2021 Feb 02, 2022	BUY	$223.92 - $287.77 $22,392 - $28,777	100 Added 4.26%	2,450 $587,000
Q3 2021 Nov 01, 2021	SELL	$282.99 - $369.05 $99,046 - $129,167	-350 Reduced 12.96%	2,350 $665,000
Q2 2021 Jul 28, 2021	BUY	$259.0 - $414.71 $25,900 - $41,471	100 Added 3.85%	2,700 $934,000
Q4 2020 Jan 25, 2021	BUY	$236.26 - $355.63 $11,813 - $17,781	50 Added 1.96%	2,600 $633,000
Q2 2020 Aug 05, 2020	BUY	$258.66 - $342.55 $38,799 - $51,382	150 Added 6.25%	2,550 $682,000
Q2 2019 Aug 05, 2019	SELL	$219.29 - $241.72 $29,384 - $32,390	-134 Reduced 5.29%	2,400 $561,000
Q1 2019 Apr 29, 2019	BUY	$216.71 - $338.96 $18,203 - $28,472	84 Added 3.43%	2,534 $598,000
Q4 2017 Feb 15, 2018	BUY	$307.64 - $344.58 $753,718 - $844,221	2,450	2,450 $0

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Vanguard Capital Wealth Advisors, based on Form 13F filings with the SEC.

Stay updated on Vanguard Capital Wealth Advisors with notifications on news.